DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

Dexcom, a medical device manufacturer that develops continuous glucose monitoring systems, received a warning letter from the FDA regarding manufacturing processes at its facilities in San Diego and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.

DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

PNC Financial Services Group Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 21.5% in the fourth ...

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% ...

DexCom (NASDAQ:DXCM – Get Free Report) had its price target increased by equities researchers at Citigroup from $101.00 to ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

DexCom, Inc.'s (NASDAQ:DXCM) stock price has dropped 12% in the previous week, but insiders who sold US$16m in ...